2007
DOI: 10.1016/j.amjcard.2006.08.034
|View full text |Cite
|
Sign up to set email alerts
|

Long-Term Versus Short-Term Clopidogrel Therapy in Patients Undergoing Coronary Stenting (from the Randomized Argentine Clopidogrel Stent [RACS] Trial)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

3
11
0

Year Published

2008
2008
2017
2017

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 29 publications
(14 citation statements)
references
References 6 publications
3
11
0
Order By: Relevance
“…However, the participants enrolled in Cordoba were significantly younger, with a higher proportion of males and smokers but lower proportion of patients with diabetes, when compared with UMASS (table 4). In addition, and as expected,30 31 aspirin use was significantly lower among the cohort in Cordoba versus the UMASS population (40% vs 80%, p<0.0001, table 4). Despite these demographic differences, a higher incidence of prolonged closure times in patients with non-cardiac symptoms was observed at both sites: that is, the proportion of participants with closure times ≥138 s was 13% vs 10% in patients with non-cardiac chest pain and 1.9% vs 2% in ACS-positive patients at UMASS versus Cordoba, respectively.…”
Section: Resultssupporting
confidence: 81%
“…However, the participants enrolled in Cordoba were significantly younger, with a higher proportion of males and smokers but lower proportion of patients with diabetes, when compared with UMASS (table 4). In addition, and as expected,30 31 aspirin use was significantly lower among the cohort in Cordoba versus the UMASS population (40% vs 80%, p<0.0001, table 4). Despite these demographic differences, a higher incidence of prolonged closure times in patients with non-cardiac symptoms was observed at both sites: that is, the proportion of participants with closure times ≥138 s was 13% vs 10% in patients with non-cardiac chest pain and 1.9% vs 2% in ACS-positive patients at UMASS versus Cordoba, respectively.…”
Section: Resultssupporting
confidence: 81%
“…Comparison of the in-hospital and long term safety profile in terms of stent thrombosis and hemorrhagic complications among octogenarians between the BMS and DES groups remained similar as demonstrated by our study. Though the absence of differences in stent thrombosis and bleeding complications between the two groups may be partly explained by the limited number of events, it is comparable to and remained similar to other randomized studies [20][21][22][23].…”
Section: Discussionsupporting
confidence: 83%
“…Table 14 (Table S17) summarizes the quality of evidence and main fi ndings from our systematic review and meta-analysis of RCTs identifi ed by a systematic literature search (updated January 2010) comparing 1 month of dual antiplatelet therapy vs 6 to 12 months in patients undergoing PCI with placement of BMS. [89][90][91][92][93] The quality of evidence is rated as low because of risk of bias, indirectness (populations varied from PCI in ACS [PCI-CURE] to elective PCI in stable angina), and large imprecision in effect estimates for all outcomes. The results suggest that dual antiplatelet therapy for 6 to 12 months signifi cantly reduces MI (RR, 0.66) but does not confi rm or exclude a signifi cant effect on mortality, stroke, or major bleeds.…”
Section: Extended Duration Of Dual Antiplatelet Therapy Following Elementioning
confidence: 99%